Skip to content

A Study to Evaluate the Feasibility of a High Add Multi Focal Contact Lens

A Study to Evaluate the Feasibility of a High Add Multi Focal Contact Lens

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01518868
Enrollment
126
Registered
2012-01-26
Start date
2012-01-31
Completion date
2012-02-29
Last updated
2020-09-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Presbyopia

Brief summary

The objective of this study is to evaluate the product performance of the investigational multifocal high add soft contact lens compared with PureVision Multi-focal contact lens on a daily wear basis.

Interventions

Worn on a daily wear basis for one week.

Worn on a daily wear basis for one week

Sponsors

Bausch & Lomb Incorporated
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Have physiologically normal anterior segments * Be adapted wearers of soft contact lenses and wear a lens in each eye. * Be presbyopic and require near add correction in each eye. * Be an adapted monovision or multifocal contact lens wearer or be an adapted spherical lens wearer who also uses spectacles for near vision correction. * Have no active ocular disease or allergic conjunctivitis. * Must not be using any topical ocular medications. * Must habitually use a lens care product for lens cleaning, disinfecting, and storage.

Exclusion criteria

* Any Grade 2 or greater finding during the slit lamp examination that, in the Investigator's judgment, interferes with contact lens wear. * Any Present finding during the slit lamp examination that, in the Investigator's judgment, interferes with contact lens wear. * Anisometropia (spherical equivalent) of greater than 2.00 D. * Any systemic disease affecting ocular health. * Using any systemic or topical medications that will affect ocular physiology or lens performance. * Allergic to any component in the study products. * Ocular astigmatism of greater than 1.00 D in either eye. * Have had any corneal surgery (ie, refractive surgery). * Uses AMO Ultra Care as their habitual lens care regimen. * Is a toric contact lens wearer. * Have worn gas permeable (GP) contact lenses within last 30 days or PMMA lenses within last 3 months. * An active ocular disease (for example but not limited to papillary conjunctivitis, any conjunctivitis: viral, bacterial, allergic), any corneal infiltrative response or are using any ocular medications.

Design outcomes

Primary

MeasureTime frameDescription
Visual AcuityAt 2 weeks follow upVisual acuity was assessed by distance high contrast logarithm of the minimum angle of resolution (logMAR).

Secondary

MeasureTime frameDescription
Symptoms/ComplaintsAt 2 weeks follow upSymptoms/complaints were assessed on a scale from 0 to 100, with 0 denoting unfavorable symptoms/complaints.

Countries

United States

Participant flow

Recruitment details

A total of 126 participants (252 eyes) were enrolled. One-half of the participants were randomized to receive the investigational contact lens during the first crossover period, and the other half were randomized to receive the PureVision contact lens during the first crossover period. The participants crossed over to the other group at 1 week.

Participants by arm

ArmCount
Overall
Participants received both treatment groups in this cross-over study.
124
Total124

Baseline characteristics

CharacteristicOverall
Age, Continuous51.6 years
STANDARD_DEVIATION 4.9
Sex: Female, Male
Female
106 Participants
Sex: Female, Male
Male
18 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
0 / 1260 / 126
serious
Total, serious adverse events
0 / 1260 / 126

Outcome results

Primary

Visual Acuity

Visual acuity was assessed by distance high contrast logarithm of the minimum angle of resolution (logMAR).

Time frame: At 2 weeks follow up

Population: There were 238 eyes assessed for visual acuity for this outcome measure. Participants/eyes received both treatment groups.

ArmMeasureValue (MEAN)Dispersion
Investigational Contact LensVisual Acuity0.079 logMARStandard Deviation 0.102
PureVision Contact LensVisual Acuity0.090 logMARStandard Deviation 0.091
Secondary

Symptoms/Complaints

Symptoms/complaints were assessed on a scale from 0 to 100, with 0 denoting unfavorable symptoms/complaints.

Time frame: At 2 weeks follow up

Population: There were 238 eyes assessed for symptoms/complaints for this outcome measure. Participants/eyes received both treatment groups.

ArmMeasureGroupValue (MEAN)Dispersion
Investigational Contact LensSymptoms/ComplaintsDryness80.3 score on a scaleStandard Deviation 20.3
Investigational Contact LensSymptoms/ComplaintsItchiness91.9 score on a scaleStandard Deviation 13.8
Investigational Contact LensSymptoms/ComplaintsRedness91.4 score on a scaleStandard Deviation 14.4
Investigational Contact LensSymptoms/ComplaintsBurning/stinging upon insertion95.6 score on a scaleStandard Deviation 8.9
Investigational Contact LensSymptoms/ComplaintsComfort upon insertion89.4 score on a scaleStandard Deviation 17
Investigational Contact LensSymptoms/ComplaintsComfort at end of day75.3 score on a scaleStandard Deviation 25.4
Investigational Contact LensSymptoms/ComplaintsOverall comfort81.6 score on a scaleStandard Deviation 20.3
Investigational Contact LensSymptoms/ComplaintsDistance vision67.7 score on a scaleStandard Deviation 29.8
Investigational Contact LensSymptoms/ComplaintsVision at intermediate distance80.5 score on a scaleStandard Deviation 22.5
Investigational Contact LensSymptoms/ComplaintsVision at near distance65.0 score on a scaleStandard Deviation 30
Investigational Contact LensSymptoms/ComplaintsOverall vision66.7 score on a scaleStandard Deviation 25.4
Investigational Contact LensSymptoms/ComplaintsEase of handling/insertion86.5 score on a scaleStandard Deviation 20.4
Investigational Contact LensSymptoms/ComplaintsEase of handling/removal88.6 score on a scaleStandard Deviation 16.3
Investigational Contact LensSymptoms/ComplaintsOverall impression73.3 score on a scaleStandard Deviation 23.5
PureVision Contact LensSymptoms/ComplaintsOverall vision56.2 score on a scaleStandard Deviation 27.5
PureVision Contact LensSymptoms/ComplaintsDryness73.3 score on a scaleStandard Deviation 26.4
PureVision Contact LensSymptoms/ComplaintsDistance vision59.3 score on a scaleStandard Deviation 30.8
PureVision Contact LensSymptoms/ComplaintsItchiness86.8 score on a scaleStandard Deviation 22.1
PureVision Contact LensSymptoms/ComplaintsEase of handling/removal86.2 score on a scaleStandard Deviation 19.6
PureVision Contact LensSymptoms/ComplaintsRedness86.9 score on a scaleStandard Deviation 23
PureVision Contact LensSymptoms/ComplaintsVision at intermediate distance70.3 score on a scaleStandard Deviation 25.8
PureVision Contact LensSymptoms/ComplaintsBurning/stinging upon insertion92.5 score on a scaleStandard Deviation 14.7
PureVision Contact LensSymptoms/ComplaintsEase of handling/insertion84.3 score on a scaleStandard Deviation 21.7
PureVision Contact LensSymptoms/ComplaintsComfort upon insertion81.5 score on a scaleStandard Deviation 25
PureVision Contact LensSymptoms/ComplaintsVision at near distance58.8 score on a scaleStandard Deviation 30.8
PureVision Contact LensSymptoms/ComplaintsComfort at end of day64.9 score on a scaleStandard Deviation 28.8
PureVision Contact LensSymptoms/ComplaintsOverall impression61.1 score on a scaleStandard Deviation 29.9
PureVision Contact LensSymptoms/ComplaintsOverall comfort70.5 score on a scaleStandard Deviation 26.7

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026